NCT00957580 is often a clinical trial with AS703026. Phase I’ll assess the results of AS703026 on patients innovative hemtopoietic malignancies. Phase II is known as a continuation of your trial with AS703026 for elderly AML patients who are not very good candidates for chemotherapy. The results of MEK inhibitors on on individuals with other cancers are also being examined in clinical trials. Selumetinib is definitely an orally-active MEK1 inhibitor which has undergone phase II clinical trials. It will be 1 from the very first MEK1 inhibitors to get evaluated in randomized phase II trials . Selumetinib has demonstrated major tumor suppressive activity in preclinical models of cancer, as well as melanoma, pancreatic, colon, lung, liver and breast cancer. The effects of selumetinib are enhanced substantially in case the tumor features a mutation that activates the Ras/Raf/MEK/ERK signaling pathway.
Selumetinib demonstrates fantastic promise in the treatment of pancreatic cancers, which normally have mutations in Ras which can cause downstream Raf/MEK/ERK pathway activation. Resulting from the regular detection of pancreatic cancer at innovative stages, it may be necessary to combine our site signal transduction inhibitor treatment with typical chemotherapy soon after surgical removal of the pancreatic cancer if possible. There’s a clinical trial combining selumetinib and erlotinib in pancreatic cancer patients who have failed gemcitabine therapy. You’ll find somewhere around 49 clinical trials with selumetinib listed around the Clinical.Trials.gov web-site. There are actually roughly 84 clinical trials with MEK inhibitors listed within the Clinical.Trials.gov webite.
There are actually 15 trials with MEK inhibitors and lung cancer, 14 trials with MEK inhibitors and pancreatic IOX2 cancer, 10 trials with MEK inhibitors and colon cancers, four trials with MEK inhibitors and leukemias, 4 trials with MEK inhibitors and HCC, four trials with MEK inhibitors and brain cancers, two trials with MEK inhibitors and breast cancer and interestingly 0 trials with MEK inhibitors and prostate cancer. Preliminary success from clinical trials have not yielded overwhelming assistance for the utilization of MEK inhibitors as a single therapeutic agent in cancer individuals who’re not pre-screened for pre-existing activation on the Ras/Raf/ MEK/ERK pathway . Without a doubt, there are 21 clinical trials listed within the Clinical.Trials.gov internet site with MEK inhibitors and melanoma individuals which normally have mutation of BRAF and hence activation of downstream MEK.
The proper pre-identification of cancer individuals who show activation from the Raf/MEK/ERK pathway could be vital for prescribing MEK inhibitors as a part of their treatment, as we’ve stated previously that MEK inhibitors are cytostatic and not cytotoxic. HCC will be the 5th most common cancer world-wide and you’ll find number of current successful therapies .